

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01   Amended 01/01/11

<b>Name of entity</b>	Alterity Therapeutics Limited
<b>ABN</b>	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Peter Marks
<b>Date of last notice</b>	30 December 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	(1) Indirect - Lampam Pty Ltd (2) Direct (3) Indirect - Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>
<b>Nature of indirect interest (including registered holder)</b>	(1) Director (2) N/A (3) SMSF
<b>Date of change</b>	(1.1) N/A (1.2) N/A (2.1) N/A (2.2) N/A (3) 07 April 2025
<b>No. of securities held prior to change</b>	(1.1) 7,185,968 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ \$0.01 (2.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ \$0.09 (2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ \$0.01 (3) NIL - FULLY PAID ORDINARY SHARES

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>Class</b>	(1.1) FULLY PAID ORDINARY SHARES (1.2) LISTED OPT EXP 31/08/2026 @ \$0.01 (2.1) UNLISTED OPT EXP 17/09/2025 @ \$0.09 (2.2) UNLISTED OPT EXP 30/12/2027 @ \$0.01 (3) FULLY PAID ORDINARY SHARES
<b>Number acquired</b>	(1.1) NIL (1.2) NIL (2.1) NIL (2.2) NIL (3) 1,818,182 - FULLY PAID ORDINARY SHARES
<b>Number disposed</b>	(1.1) NIL (1.2) NIL (2.1) NIL (2.2) NIL (3) NIL
<b>Value/Consideration</b>	(1.1) N/A (1.2) N/A (2.1) N/A (2.2) N/A (3) \$20,000 - \$0.011 PER ORDINARY SHARE
<b>No. of securities held after change</b>	(1.1) 7,185,968 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ \$0.01 (2.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ \$0.09 (2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ \$0.01 (3) 1,818,182 - FULLY PAID ORDINARY SHARES
<b>Nature of change</b>	(1.1) N/A (1.2) N/A (2.1) N/A (2.2) N/A (3) Placement @ \$0.011 - Direct

## Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b>	N/A
<b>Interest after change</b>	N/A

### Part 3 - <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.  
01/01/2011 Appendix 3Y Page 3

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01   Amended 01/01/11

<b>Name of entity</b>	Alterity Therapeutics Limited
<b>ABN</b>	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Lawrence Gozlan
<b>Date of last notice</b>	30 December 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	(1) Direct (2) Indirect - Montoya Pty Ltd <Buttercup A/C>
<b>Nature of indirect interest (including registered holder)</b>	(1) N/A (2) Director
<b>Date of change</b>	(1.1) N/A (1.2) N/A (2) 07 April 2025
<b>No. of securities held prior to change</b>	(1.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ \$0.09 (1.2) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ \$0.01 (2) NIL - FULLY PAID ORDINARY SHARES
<b>Class</b>	(1.1) UNLISTED OPT EXP 17/09/2025 @ \$0.09 (1.2) UNLISTED OPT EXP 30/12/2027 @ \$0.01 (2) FULLY PAID ORDINARY SHARES
<b>Number acquired</b>	(1.1) NIL (1.2) NIL (2) 4,545,455 - FULLY PAID ORDINARY SHARES

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>Number disposed</b>	(1.1) NIL (1.2) NIL (2) NIL
<b>Value/Consideration</b>	(1.1) N/A (1.2) N/A (2) \$50,000 - \$0.011 PER FULLY PAID ORDINARY SHARE
<b>No. of securities held after change</b>	(1.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ \$0.09 (1.2) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ \$0.01 (2) 4,545,455 - FULLY PAID ORDINARY SHARES
<b>Nature of change</b>	(1.1) N/A (1.2) N/A (2) Placement @ \$0.011

## Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b>	N/A
<b>Interest after change</b>	N/A

## Part 3 - <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01   Amended 01/01/11

<b>Name of entity</b>	Alterity Therapeutics Limited
<b>ABN</b>	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Brian Meltzer
<b>Date of last notice</b>	30 December 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	(1) Direct (2) Indirect - BT PORTFOLIO SERVICES
<b>Nature of indirect interest (including registered holder)</b>	(1) N/A (2) SMSF
<b>Date of change</b>	(1.1) 07 April 2025 (1.2) N/A (1.3) N/A (1.4) N/A (2) N/A
<b>No. of securities held prior to change</b>	(1.1) 7,142,857 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ \$0.01 (1.3) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ \$0.09 (1.4) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ \$0.01 (2) 326,666 - FULLY PAID ORDINARY SHARES

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>Class</b>	(1.1) FULLY PAID ORDINARY SHARES (1.2) LISTED OPT EXP 31/08/2026 @ \$0.01 (1.3) UNLISTED OPT EXP 17/09/2025 @ \$0.09 (1.4) UNLISTED OPT EXP 30/12/2027 @ \$0.01 (2) FULLY PAID ORDINARY SHARES
<b>Number acquired</b>	(1.1) 2,272,727 - FULLY PAID ORDINARY SHARES (1.2) NIL (1.3) NIL (1.4) NIL (2) NIL
<b>Number disposed</b>	(1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (2) NIL
<b>Value/Consideration</b>	(1.1) \$25,000 - \$0.011 PER FULLY PAID ORDINARY SHARE (1.2) N/A (1.3) N/A (1.4) N/A (2) N/A
<b>No. of securities held after change</b>	(1.1) 9,415,584 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ \$0.01 (1.3) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ \$0.09 (1.4) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ \$0.01 (2) 326,666 - FULLY PAID ORDINARY SHARES
<b>Nature of change</b>	(1.1) Placement @ \$0.011 - Direct (1.2) N/A (1.3) N/A (1.4) N/A (2) N/A

## Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b>	N/A
<b>Interest after change</b>	N/A

### Part 3 - <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.  
01/01/2011 Appendix 3Y Page 3